慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析*

doi:10.3969/j.issn.1672-5069.2021.04.011

摘要/Abstract

摘要： 目的探讨慢性丙型肝炎(CHC)患者血清microRNA-1273g-3p水平预测发生肝硬化的价值。方法 2018年3月～2020年8月我院收治的CHC患者125例,采用实时荧光定量逆转录聚合酶链反应(qRT-PCR)法检测外周血microRNA-1273g-3p水平。应用Logistic回归分析CHC患者发生肝硬化的影响因素,绘制受试者工作特征曲线(ROC),计算曲线下面积,评估血清microRNA-1273g-3p水平预测CHC患者发生肝硬化的价值。结果在本组125例CHC患者中,发现肝硬化42例(33.6%);肝硬化组BMI高、有输血史、血脂异常、未抗病毒治疗和血清microRNA-1273g-3p水平与CHC患者比,差异显著(P均<0.05),肝硬化组病程为(12.4±2.7)年,显著长于CHC组[(8.2±2.1)年,P＜0.01],肝硬化组血清microRNA-1273g-3p水平为(2.1±0.5),显著高于CHC组[(1.3±0.3),P＜0.01];经Logistic回归分析发现,以上因素均为影响CHC患者发生肝硬化的独立危险因素;经ROC分析显示,以血清microRNA-1273g-3p水平1.56为最佳截断点,其AUC值为0.844(95%CI:0.768～0.902),预测CHC患者发生肝硬化的灵敏度为78.6%(33/42,95%CI:73.1%～83.2%),特异度为86.8%(72/83,95%CI:82.5%～90.6%),准确度为90.4%(113/125,95%CI:73.1%～83.2%)。结论检测血清microRNA-1273g-3p水平可能帮助预测CHC患者发生肝硬化,对及时诊治和管理具有一定的临床意义。

关键词: 慢性丙型肝炎, 微小RNA-1273g-3p, 诊断

Abstract: Objective The aim of this study was to investigate the predictive value of liver cirrhosis by serum microRNA-1273g-3p levels in patients with chronic hepatitis C (CHC). Methods 125 patients with CHC were admitted to our hospital between March 2018 and August 2020, and serum microRNA-1273g-3p levels were detected by real-time fluorescent quantitative RT-polymerase chain reaction (qRT-PCR). The Logistic regression analysis was applied to reveal the influencing factors for liver cirrhosis occurrence. The receiver operating characteristic curve (ROC) was drawn to analyze the predictive value of serum microRNA-1273g-3p for liver cirrhosis. Results Out of our series in this study, 42 patients with CHC were found to have liver cirrhosis based on the clinical, blood biochemical and imaging examination; the BMI, blood transfusion history, dyslipidemia, failure to adhere to antiviral treatment and serum microRNA-1273g-3p levels in patients with liver cirrhosis were significantly different compared to those without (all P < 0.05), the disease course in patients with liver cirrhosis was (12.4±2.7) yr, significantly longer than [(8.2±2.1) yr, P < 0.01] in patients without, and serum microRNA-1273g-3p level in the cirrhotics was (2.1±0.5), significantly higher than t [(1.3±0.3), P < 0.01] in patients without liver cirrhosis; the Logistic regression analysis showed that all the parameters mentioned above were the independent risk factors for CHC patients having liver cirrhosis; the ROC analysis showed that the optimal cut-off value of serum microRNA-1273g-3p level was 1.56, and its AUC was 0.844(95%CI:0.768-0.902), with the sensitivity of 78.6%(33/42, 95%CI:73.1%-83.2%), the specificity of 86.8%(72/83, 95%CI:82.5%-90.6%) and the accuracy of 90.4%(113/125, 95%CI:73.1%-83.2%) in predicting the concomitant liver cirrhosis. Conclusion Serum microrna-1273g-3p levels in CHC patients with liver cirrhosis increase, and regular surveillance might help manage the patients and give them an appropriate treatment.

Key words: Hepatitis C, MicroRNA-1273g-3p, Diagnosis

王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.

Wang Jia’ni, Liu Yong, Zhou Xin, et al. Predictive value of liver cirrhosis by serum microRNA-1273g-3p levels in patients with chronic hepatitis C[J]. Journal of Practical Hepatology, 2021, 24(4): 496-499.

参考文献

[1] Besheer T, Arafa M, El-Maksoud MA, et al. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: Role of ABCB11 genotype polymorphism and plasma bile acid levels. TurkJ Gastroenterol, 2018, 29(3):299-307.
[2] 杨才勇, 陈娜, 李奎, 等. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨. 实用肝脏病杂志, 2019, 22(6):868-871.
[3] Rashad NM, El-Shal AS, Shalaby SM, et al. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma. Mol Cell Biochem, 2018, 47(1-2):125-136.
[4] Weis A, Marquart L, Calvopina DA, et al. Serum microRNAs as biomarkers in hepatitis C: Preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma. Int J Mol Sci, 2019, 20(4):864.
[5] 林升龙, 王香梅, 马华晳, 等. 基于芯片和公共数据库数据分析微RNA在乙型肝炎病毒感染中的可能机制. 中华传染病杂志, 2020, 38(11):717-722.
[6] Nan Y, Niu X, Wang R, et al. microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. Exp Ther Med, 2019, 17(3):1817-1824.
[7] 纪冬, 游绍丽, 辛绍杰. 《丙型肝炎防治指南(2015年更新版)》要点解读. 传染病信息, 2016, 29(1):20-23.
[8] 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南. 实用肝脏病杂志, 2019, 22(6):18-34.
[9] Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm. World J Gastroenterol, 2019, 25(29):3929-3940.
[10] Hwang JP, LoConte NK, Rice JP, et al. Oncologic implications of chronic hepatitis C virus infection. J Oncol Pract, 2019, 15(12):629-637.
[11] Hedenstierna M, Nangarhari A, El-Sabini A, et al. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. J Viral Hepat, 2018, 25(7):802-810.
[12] Lowey B, Hertz L, Chiu S, et al. Hepatitis C virus infection induces hepatic expression of NF-κB-inducing kinase and lipogenesis by downregulating miR-122. mBio, 2019, 10(4):e01617-619.
[13] Santangelo L, Bordoni V, Montaldo C, et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int, 2018, 38(10):1741-1750.
[14] Horii R, Honda M, Shirasaki T, et al. MicroRNA-10a impairs liver metabolism in hepatitis C virus-related cirrhosis through deregulation of the circadian clock gene brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1. Hepatol Commun, 2019, 3(12):1687-1703.
[15] Mohamed AA, Omar AAA, El-Awady RR, et al. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. J Transl Int Med, 2020, 8(1):32-40.
[16] El-Hefny M, Fouad S, Hussein T, et al. Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. J Med Virol, 2019, 91(1):93-101.
[17] Lendvai G, Szekerczés T, Gyöngyösi B, et al. MicroRNA expression in focal nodular hyperplasia in comparison with cirrhosis and hepatocellular carcinoma. Pathol Oncol Res, 2019, 25(3):1103-1109.
[18] Hassan AS, Elgendy NA, Tawfik NA, et al. Serum miR-483-5p and miR-133a as biomarkers for diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. Egypt J Immunol, 2019, 26(2):31-40.
[19] Liu B, Yang XF, Liang XP, et al. Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(23):8431-8437.
[20] Nasser MZ, Zayed NA, Mohamed AM, et al. Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab J Gastroenterol, 2019, 20(4):198-204.

慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*

Predictive value of liver cirrhosis by serum microRNA-1273g-3p levels in patients with chronic hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[2]	安红杰, 徐金凤, 耿华, 葛志胜, 何文艳, 赵崇山, 高美丽, 陈俊, 周东方. FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 492-495.
[3]	欧南, 魏梅, 王劲, 彭正伟. 应用MRI多回波水脂分离技术评估非酒精性脂肪性肝病患者肝脏脂肪含量效能研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 508-511.
[4]	殷志勇, 王连双, 张瑶. 超声检查门静脉海绵样变特征表现[J]. 实用肝脏病杂志, 2021, 24(4): 540-543.
[5]	陈永超, 周旺, 李岩, 张超学. 超声造影指导肝穿刺对肝脏占位性病变的诊断价值研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 569-572.
[6]	朱文莉, 李宝新, 张穿洋, 李晓冉, 傅晓明. 肝包虫病与肝囊肿CT表现比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 577-580.
[7]	郝肖伟, 白娜, 郭小军, 陈永刚. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清A-FABP水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(3): 347-350.
[8]	贾群玲, 徐志宾, 韩舒. 非酒精性脂肪性肝病患者磁共振质子密度脂肪分数变化[J]. 实用肝脏病杂志, 2021, 24(3): 359-362.
[9]	刘彦荣, 王苗, 曾果, 许晓亮. MRI弥散加权成像对原发性硬化性胆管炎患者肝纤维化评估价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 375-378.
[10]	南东, 洪金玲, 姜海宇. 应用DCE-MRI技术评估乙型肝炎肝硬化患者食管胃底静脉曲张严重程度的效能分析[J]. 实用肝脏病杂志, 2021, 24(3): 407-410.
[11]	王耀政, 王瑜琳, 林毅. F-FDG PET/CT诊断胆管细胞癌分期价值研究[J]. 实用肝脏病杂志, 2021, 24(3): 427-430.
[12]	干艳英, 钟凯, 官燕玲, 李慧敏. 三种影像学方法诊断肝外胆管结石比较研究[J]. 实用肝脏病杂志, 2021, 24(3): 439-442.
[13]	韩文有, 李向军, 赵森峰, 徐俊梅, 刘博. 术前胆汁CT值测定诊断胆囊泥沙样结石的应用价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 443-446.
[14]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[15]	白洁, 郑素军. 重视和推进对遗传代谢性肝病的认识和研究[J]. 实用肝脏病杂志, 2021, 24(2): 153-155.